Notice of J-CMA (Japan Central Medical Association) pricing deliberations. It is announced that the pricing for Telomerasine\u00ae injection will be deliberated by the J-CMA plenary session, with the impact on the 2026 fiscal year results under review. Commercial launch is planned for the 2026 fiscal year as scheduled.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"OncoCyte Bio-Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4588-20260805-01.pdf","jir_short_summary":"Notice of J-CMA (Japan Central Medical Association) pricing deliberations. It is announced that the pricing for Telomerasine\u00ae injection will be deliberated by the J-CMA plenary session, with the impact on the 2026 fiscal year results under review. Commercial launch is planned for the 2026 fiscal year as scheduled.","jir_summary":"### Key takeaways\nOncoCyte Bio-Pharma announced that the pricing deliberation for Telomerasine\u00ae Injection (OBP-301) will be held at the J-CMA plenary session. The progression of pricing deliberations and post-approval launch plan are indicated, with the impact on the 2026 fiscal year results undetermined.\n\n### Outlook and impact for investors\nRevenue contribution from this product will vary depending on the pricing deliberation outcome. At present, the impact amount is unknown, and it is necessary to watch the deliberations and launch progress closely.","jir_financial_highlights":"Impact on the 2026 fiscal year results: Unknown (Unknown)","jir_category":"","jir_hashtags":"#OncoCyteBioPharma, #IR, #JPStocks","jir_key_figures":"Impact on the 2026 fiscal year results: Unknown\nPlanned launch timing: 2026 fiscal year (planned)\nPricing deliberation: to be reviewed at the J-CMA plenary session","jir_meta_title":"OncoCyte Bio-Pharma: Notice of Pricing Deliberation | Planned 2026 December Revenue","jir_meta_description":"OncoCyte Bio-Pharma announces that Telomerasine\u00ae Injection's pricing deliberation will be reviewed at the J-CMA plenary session. Impact on the 2026 fiscal year results is as yet uncertain. Monitor progress of deliberations and launch timing.","jir_og_title":"OncoCyte Bio-Pharma: Notice of Pricing Deliberation","jir_og_description":"Pricing deliberation for Telomerasine\u00ae Injection is scheduled for discussion at the J-CMA plenary session. Impact on results is not yet determined; planned launch in the 2026 fiscal year.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-94459","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n